NCT00612625

Brief Summary

The ability of glucagon-like peptide 1 to enhance beta-cell responsiveness to I.v. glucose is impaired in patients with type 2 diabetes mellitus compared with healthy individuals. We investigated whether 4 weeks of near-normalisation og blood glucose improves the potentiation of glucose-stimulated insulin secretion by GLP-1

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
9

participants targeted

Target at below P25 for not_applicable diabetes-mellitus-type-2

Timeline
Completed

Started Feb 2004

Shorter than P25 for not_applicable diabetes-mellitus-type-2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2004

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2004

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2004

Completed
3.1 years until next milestone

First Submitted

Initial submission to the registry

January 16, 2008

Completed
27 days until next milestone

First Posted

Study publicly available on registry

February 12, 2008

Completed
Last Updated

February 12, 2008

Status Verified

January 1, 2008

Enrollment Period

5 months

First QC Date

January 16, 2008

Last Update Submit

February 11, 2008

Conditions

Outcome Measures

Primary Outcomes (1)

  • insulin secretion rate (ISR) were derived by deconvolution of c-peptide. ISR is expressed as pmol/kg/min

    180 minutes

Secondary Outcomes (1)

  • The calculated ISR values was plotted against the ambient plasma glucose. The slopes of this linear relationships were calculated by cross-correlation analysis and is and estimation of beta-cell responsiveness (pmol/kg/min)/mmol/l

    180 minutes

Study Arms (2)

GLP-1

EXPERIMENTAL

A graded glucose infusion with an infusion of GLP-1 (1½ pmol/kg/min)

Drug: glucagon-like peptide-1

Saline

EXPERIMENTAL

A graded glucose infusion together with a continuous infusion of saline

Drug: Saline

Interventions

continuous infusion of GLP-1 (1½ pmol/kg/min)

GLP-1
SalineDRUG

continuous infusion of saline

Saline

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-70 years
  • Type 2 diabetes diagnosed after 30 years of age
  • BMI \> 25

You may not qualify if:

  • Severe complications to diabetes
  • Abnormal liver og kidney function
  • Haemoglobin below the lower limit
  • Macroalbuminuria
  • Systemic disease
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dept. of Endocrinology, Hvidovre Hospital

Copenhagen, Denmark

Location

Related Publications (1)

  • Hojberg PV, Zander M, Vilsboll T, Knop FK, Krarup T, Volund A, Holst JJ, Madsbad S. Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia. 2008 Apr;51(4):632-40. doi: 10.1007/s00125-008-0943-x. Epub 2008 Feb 22.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Glucagon-Like Peptide 1Sodium Chloride

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Glucagon-Like PeptidesProglucagonGastrointestinal HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Patricia V Højberg, MD, PHD

    University Hospital Hvidovre

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 16, 2008

First Posted

February 12, 2008

Study Start

February 1, 2004

Primary Completion

July 1, 2004

Study Completion

December 1, 2004

Last Updated

February 12, 2008

Record last verified: 2008-01

Locations